Since, in the context of CeD, T cells in the gut contribute to damage of the epithelial tissue, it is hypothesized that any medication targeting the CCR9-CCL25 interaction could have a positive impact on reductions in intestinal inflammation. The gene discussed is CCR9; the disease is cranioectodermal dysplasia.